Merck & Co./$MRK
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Merck & Co.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
Ticker
$MRK
Sector
Primary listing
NYSE
Employees
74,000
Headquarters
Website
Merck & Co. Metrics
BasicAdvanced
$210B
12.99
$6.49
0.39
$3.20
3.85%
Price and volume
Market cap
$210B
Beta
0.39
52-week high
$117.90
52-week low
$73.31
Average daily volume
12M
Dividend rate
$3.20
Financial strength
Current ratio
1.424
Quick ratio
0.82
Long term debt to equity
69.238
Total debt to equity
72.161
Dividend payout ratio (TTM)
48.95%
Interest coverage (TTM)
18.77%
Profitability
EBITDA (TTM)
29,157
Gross margin (TTM)
77.41%
Net profit margin (TTM)
25.79%
Operating margin (TTM)
38.95%
Effective tax rate (TTM)
14.32%
Revenue per employee (TTM)
$860,000
Management effectiveness
Return on assets (TTM)
13.01%
Return on equity (TTM)
35.42%
Valuation
Price to earnings (TTM)
12.987
Price to revenue (TTM)
3.34
Price to book
4.38
Price to tangible book (TTM)
19.45
Price to free cash flow (TTM)
14.433
Free cash flow yield (TTM)
6.93%
Free cash flow per share (TTM)
5.835
Dividend yield (TTM)
3.80%
Forward dividend yield
3.85%
Growth
Revenue change (TTM)
1.82%
Earnings per share change (TTM)
20.41%
3-year revenue growth (CAGR)
3.63%
10-year revenue growth (CAGR)
4.68%
3-year earnings per share growth (CAGR)
-0.21%
10-year earnings per share growth (CAGR)
6.60%
3-year dividend per share growth (CAGR)
5.65%
10-year dividend per share growth (CAGR)
5.91%
What the Analysts think about Merck & Co.
Analyst ratings (Buy, Hold, Sell) for Merck & Co. stock.
Merck & Co. Financial Performance
Revenues and expenses
Merck & Co. Earnings Performance
Company profitability
Merck & Co. News
AllArticlesVideos
Vets and Pet-Owners See Gaps in Flea and Tick Prevention, Highlighting Need for Year-Round Care, New Merck Animal Health Global Survey Finds
Business Wire·4 hours ago
KEYTRUDA® (pembrolizumab) plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free and Overall Survival and Pathologic Complete Response Rate for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery
Business Wire·1 week ago
Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges
WSJ·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
Sept15
Merck & Co.
Dividend·Ex-dividend
Oct7
Merck & Co.
Dividend·Payment
$0.81Per share
FAQs
What’s the current market cap for Merck & Co. stock?
Merck & Co. (MRK) has a market cap of $210B as of August 19, 2025.
What is the P/E ratio for Merck & Co. stock?
The price to earnings (P/E) ratio for Merck & Co. (MRK) stock is 12.99 as of August 19, 2025.
Does Merck & Co. stock pay dividends?
Yes, the Merck & Co. (MRK) stock pays dividends to shareholders. As of August 19, 2025, the dividend rate is $3.2 and the yield is 3.85%. Merck & Co. has a payout ratio of 48.95% on a trailing twelve-month basis.
When is the next Merck & Co. dividend payment date?
The next Merck & Co. (MRK) dividend payment is scheduled for October 07, 2025.
What is the beta indicator for Merck & Co.?
Merck & Co. (MRK) has a beta rating of 0.39. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.